Company Performance Metrics
- Howard Stevens: Founder & Executive Chairman
- Carol Thomson: CEOPast Role: University of Strathclyde, Research Policy Manager
BDD is a specialist drug formulation company providing expertise across all areas of drug delivery. We offer a full service package to fit individual needs from troubleshooting, formulation development, in vitro and in vivo testing.
Our patented time release technology OralogiK provides unrivaled control of drug release at the right place and
time.
OralogiK has been validated in numerous clinical studies, enables the oral delivery of single, multi-dose or combination drugs at pre-determined times between one and 12 hours after being swallowed by the patient. This facilitates such benefits as: night time dosing of a drug to be delivered pre-wakeup multi-phased delivery of one or more drugs (immediate and delayed) to allow once-a-day dosing or for pre-treatment by one drug before the delivery of a second delivery of drugs to a specific regions of the digestive system (e.g. the colon) BDD also specialize in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences.
Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report.
